Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Cold Spring Harb Perspect Med 2:a006338a006338
Bananas are a low- to medium-glycemic food depending on the ripeness of the fruit (meaning: the more ripe the banana the higher the glycemic index) which isnt a good option when trying to control glucose levels
Therefore, searching for potential adjuvant therapies with hepatoprotective capacities to be used during chemotherapy is widely adopted (Liang et al., 2021) with the need to understand the mechanisms underlying MTX-induced liver toxicity